← Back to Search

Alpha-2A Adrenergic Receptor Agonist

Guanfacine for Borderline Personality Disorder

N/A
Waitlist Available
Led By Antonia S. New, M.D.
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test whether the drug guanfacine can help treat borderline personality disorder by improving attention and behavior.

Who is the study for?
This trial is for men and women aged 18 to 55 who have been diagnosed with borderline personality disorder, specifically those showing impulsive aggression. Participants should not be dependent on substances, suffering from major depression, bipolar disorder, schizophrenia-spectrum disorders, or currently taking psychiatric medications.Check my eligibility
What is being tested?
The study is testing the effectiveness of guanfacine (Tenex) in treating symptoms of BPD. Guanfacine works by stimulating brain activity in areas responsible for attention and behavior control. The goal is to see if it can help manage mood instability and impulsive aggression associated with BPD.See study design
What are the potential side effects?
While the specific side effects for this trial are not listed, guanfacine commonly causes drowsiness, headache, fatigue, stomach pain and may lower blood pressure leading to dizziness or fainting.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 55 years old and have been diagnosed with borderline personality disorder with impulsive aggression.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
measures of affective disturbance
measures of impulsive aggression
measures of overall clinical status
+1 more

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
857 Previous Clinical Trials
524,271 Total Patients Enrolled
3 Trials studying Borderline Personality Disorder
287 Patients Enrolled for Borderline Personality Disorder
Antonia S. New, M.D.Principal InvestigatorIcahn School of Medicine at Mount Sinai

Media Library

Guanfacine (Alpha-2A Adrenergic Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT00358969 — N/A
Borderline Personality Disorder Research Study Groups:
Borderline Personality Disorder Clinical Trial 2023: Guanfacine Highlights & Side Effects. Trial Name: NCT00358969 — N/A
Guanfacine (Alpha-2A Adrenergic Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00358969 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age restriction for this trial extend beyond 65 years old?

"The target demographic for this clinical trial are individuals aged 18 to 55."

Answered by AI

Are there currently any vacancies in the research program?

"As per the information hosted on clinicaltrials.gov, enrollment for this particular medical trial has concluded and is no longer accepting patients. The original post was made July 1st 2006, with a final update occurring one month later on July 31st of that same year. Despite being closed to recruitment, there are still 956 other studies actively seeking participants at this time."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
New York
How old are they?
18 - 65
What site did they apply to?
Mount Sinai Hospital - Mood & Personality Research Group
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Guanfacine to Treat Borderline Personality Disorder
2006. "Guanfacine to Treat Borderline Personality Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00358969.
All > Obsessive Compulsive Disorder > Borderline Personality Disorder
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top